To use all functions of this page, please activate cookies in your browser.
My watch list
my.chemeurope.com
my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Volociximab
Volociximab (also known as M200) is a chimeric monoclonal antibody jointly developed by PDL BioPharma and Biogen Idec for treatment of a variety of advanced solid tumors. It binds to and inhibits the functional activity of α5β1 integrin.
|
||||||||||||||||||||||||||||||||||||||||||||||
| This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Volociximab". A list of authors is available in Wikipedia. | ||||||||||||||||||||||||||||||||||||||||||||||
Last viewed
- Identifying toxic materials in water with machine learning - New research can quickly identify toxins from oil sands and tailing ponds
- Cholestyramine
- FreeSharing_Network
- X-rays uncover a hidden property that leads to failure in a lithium-ion battery material - Experiments at SLAC and Berkeley Lab uproot long-held assumptions and will inform future battery design
- Spherulite
